Written defaultedefaultvidence from Vertex Pharmaceuticals UKdefault (LTC 50)default&#xa0;default&#xa0;default1.1.
default&#xa0;&#xa0; 
defaultVertex’s product 
defaultKal
defaultydeco
default (
defaultivacaftor
default) 
defaultis the first in a new class of innovative medicines that treats the underlying causes of 
defaultcystic fibrosis, a genetic disease affecting approximately 10,000 people in the UK.
default 
default&#xa0;
default1.2.
default&#xa0;&#xa0; 
defaultKalydeco has been available to all patients with the G551D mutation in England since 1
defaultst
default January 2013.
default 
defaultThis has a number of implications for the commissioning and delivery of specialised services for cystic fibrosis
default, particularly in relation to NICE’s appraisal process for Highly Specialised Technologies and NHS England’s 
defaultclinical commissioning policies for higher-cost medicines
default.
default 
default&#xa0;default&#xa0;default2.1.
default&#xa0;&#xa0; 
defaultVertex is a global health sciences company that aims to accelerate the discovery, development, and commercialisation of critical medicines for life-threatening diseases including 
defaultcystic fibrosis
default, hepatitis C, and epilepsy.
default 
default&#xa0;
default2.2.
default&#xa0;&#xa0; 
defaultIn 1998, Vertex established its first global research and development
default 
defaultsite in the 
defaultUK
default. Researchers at Vertex’s approximately 150-person UK site are focused on discovering new medicines for a variety of cancer types and 
defaultneuroinflammatory
default diseases.
default 
default&#xa0;default&#xa0;default3.1.
default&#xa0;&#xa0; 
defaultCystic fibrosis
default is 
defaulta genetic disease
default affecting 
defaultapproximately 
default10
default,000 people 
defaultin the UK.
default 
defaultIt is a complex and multi-system disease that causes the internal organs, particularly the lungs and dig
defaultestive system, to produce thick
default sticky mucus that eventually leads to death from respiratory failure.
default 
defaultIn 2011 t
defaulthe median age at death for 
defaultcystic fibrosis 
defaultpatients 
defaultwas 26 years
default.
default 
default&#xa0;default3.2.
default&#xa0;&#xa0; 
defaultCystic fibrosis is also associated with other long-term conditions including 
defaultdiabetes, 
defaultinfertility
default,
default and osteoporosis.
default 
default&#xa0;default3.3.
default&#xa0;&#xa0; 
defaultThe 
defaultcare of 
defaultchildren and adults with 
defaultcystic fibrosis 
defaultis coordinated by specialised services
default that are directly commissioned by NHS England
default.
default 
defaultThese specialised services provide 
defaultcare from a multidisciplinary team including specialist doctors, nurses, and allied health professionals.
default 
default&#xa0;
default&#xa0;default4.1.
default&#xa0;&#xa0; 
defaultVertex’s product 
defaultKalydeco 
defaultreceived regulatory approval for the 
defaulttreatment of 
defaultcystic fibrosis
default in patients aged six years and older who have a G551D mutation in the 
defaultcystic fibrosis
default 
defaulttransmembrane
default conductance regulator (
defaultCFTR
default)
default gene from the European Medicines Agency in July 2012.
default 
default&#xa0;default4.2.
default&#xa0;&#xa0; 
defaultIn 2011 there were 466 cystic fibrosis patients with a copy of this mutation in UK.
default 
defaultDue to this small patient population 
defaultKalydeco is 
defaultw
defaultidely recognised as an ultra-orphan medicine
default 
default(i.e. a treatment for a very rare disease).
default 
default&#xa0;
default4.3.
default&#xa0;&#xa0; 
defaultKalydeco
default 
defaultis the first in a new class of innovative medicines 
defaultthat 
defaulttreats 
defaultthe underlying causes of 
defaultcystic fibrosis
default.
default 
defaultThe results of clinical trials indicate that treatment with Kalydeco could lead to a 10-year increase in life-expectancy and a significant improvement in quality of life.
default 
default4.4.
default&#xa0;&#xa0; 
defaultKalydeco
default 
defaulthas been 
defaultavailable to all patients with the 
defaultG551D mutation in England since 1
defaultst
default January 2013 following a commissioning decision made by the Clinical Priorities Advisory Group.
default 
defaultSince 1
defaultst
default April 2013 it has been commissioned on a national basis by NHS England.
default 
default&#xa0;
default&#xa0;default5.1.
default&#xa0;&#xa0; 
defaultUK clinicians have noted that Kalydeco 
default‘is life changing for the few patients with cystic fibrosis for whom it is indicated’ and, as the first medicine of its kind, 
default‘has the potential to transform cystic fibrosis
default care’
default.
default 
defaultT
defaulthis 
defaulttransformation in cystic fibrosis care 
defaultmay require 
defaultchanges to the way that specialised services and treatments for the disease are commissioned and delivered.
default 
default&#xa0;
defaultNational Institute for Health and Care Excellencedefault&#xa0;
default5.2.
default&#xa0;&#xa0; 
defaultThe National Institute for Health and Care Excellence (NICE) assumed responsibility for the appraisal of H
defaultighly Specialised Technologies (i.e. 
defaultultra-orphan medicines
default) 
defaulton 1
defaultst
default April 2013.
default 
defaultIt is essential that NICE’s appraisal process for Highly Specialised Technologi
defaultes recognises the value of innovative medicines for th
defaulte treatment of very rare clinical subsets of more common diseases, 
defaultparticularly long-ter
defaultm conditions for which there is 
defaultno cure, 
defaultand takes this into account when making its recommendations.
default 
default&#xa0;defaultNHS Englanddefault&#xa0;
default5.3.
default&#xa0;&#xa0; 
defaultAlthough t
defaulthe majority of medicines for the treatment of cystic fibrosis are funded 
defaultusing 
defaultthe Payment by Results 
defaultsystem, 
defaultcertain higher-cost medicines are 
defaultdirectly commissioned
default by NHS England.
default 
defaultIt is essential that this direct commissioning continues to ensure 
defaultcystic fibrosis patients have 
defaultequitable access to
default highe
defaultr-cost medicines across England
default.
default 
default&#xa0;
default5.4.
default&#xa0;&#xa0; 
defaultI
defaultf Kalydeco and other innovative new medicine for cystic fibrosis lead to a reduction in 
defaultexacerbations and 
defaulthospital admissions, 
defaultit may 
defaultbe possible to redesign some services to allow patients to receive a larger proportion of their 
defaultcare 
defaultin the community
default.
default 
defaultThis would be likely to lead to further improvements to patients’ quality of life and reduce the costs of providing specialist services in a hospital setting.
default 
defaultMay 2013
default 
defaultCystic fibrosis
default Trust.
default 
defaultAnnual Data Report 2011 (2013).
default 
defaultAvailable at https://www.cysti
defaultcystic fibrosis
defaultibrosis.org.uk/media/82506/CR_Annual_Data_Report_2011_Jan_13.pdf
default NHS England.
default 
defaultClinical Commissioning Policy: 
defaultIvacaftor
default for Cystic Fibrosis (2013).
default 
defaultAvailable at http://www.england.nhs.uk/wp-content/uploads/2013/04/a01-p-b.pdf
default Cystic fibrosis Trust.
default 
defaultAnnual Data Report 2011 (2013).
default 
defaultAvailable at https://www.cysticystic fibrosisibrosis.org.uk/media/82506/CR_Annual_Data_Report_2011_Jan_13.pdf
default All Wales Medicines Strategy Group.
default 
defaultClinical Expert Summary (2013).
default 
defaultAvailable at http://www.wales.nhs.uk/sites3/Documents/371/Enc%207%20Appx%203%20ivacaftor%20%28Kalydeco%29%20Clinical%20Expert%20Summary.pdf
default